EXACT Sciences Corporation Stock News

The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of

LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recomme

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.

Exact Sciences stock tumbled late Wednesday after the Cologuard-maker reported wide losses, though sales came in ahead of expectations.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow

In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered

While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three c

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 20